A signal seeking window trial of AZD8931 in patients with resectable non-small cell lung cancer
Latest Information Update: 12 Feb 2019
Price :
$35 *
At a glance
- Drugs Sapitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 07 Feb 2019 Status changed from recruiting to discontinued.
- 18 Sep 2012 New trial record